RhumbLine Advisers’s Bicycle Therapeutics BCYC Stock Holding History
Bought
Maintained
Sold
Other funds holding BCYC
BBA
LFCM
RhumbLine Advisers's BCYC Position: Q3 2026 in Review
RhumbLine Advisers increased its Bicycle Therapeutics (BCYC) stake by 31% in Q3 2026, buying an estimated $19.9K and bringing the position to 20,888 shares worth $76.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3566.
RhumbLine Advisers first reported a position in BCYC in Q2 2023 and has held it in 14 quarters since. The position peaked at $79.1K in Q4 2025. 90 funds tracked by Wall St. Rank hold BCYC as of Q3 2026.
- RhumbLine Advisers held 20,888 shares of Bicycle Therapeutics worth $76.9K as of Q3 2026.
- RhumbLine Advisers bought 4,921 Bicycle Therapeutics shares in Q3 2026, an estimated $19.9K.
- Bicycle Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3566 holding.
- RhumbLine Advisers first reported a position in Bicycle Therapeutics in Q2 2023 and has held it in 14 quarters since.
- RhumbLine Advisers's Bicycle Therapeutics position peaked at $79.1K in Q4 2025.
- 90 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q3 2026.
Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.